Tesamorelin – Ipamorelin Blend – 15mg/5mg

Description

Description

The Tesamorelin/Ipamorelin blend combines two complementary growth hormone secretagogues working through distinct receptor pathways. Tesamorelin, a stabilized GHRH analog, activates pituitary GHRH receptors, while Ipamorelin mimics ghrelin to stimulate GHS-R1a receptors independently. Their dual-pathway action amplifies natural GH pulsatility, supporting research into body composition, visceral fat reduction, metabolic health, and tissue repair. Currently for research use only.

PURITY

99% HPLC

RUO

Research Use Only
Not for human or veterinary use.

Price: $150.00

Dual-Pathway GH Amplification — Tesamorelin activates GHRH receptors while Ipamorelin simultaneously stimulates GHS-R1a (ghrelin) receptors, engaging two independent signaling cascades in the anterior pituitary. This complementary mechanism produces a synergistic GH response greater than either peptide achieves alone, more closely mimicking the body’s natural pulsatile GH release pattern.
Clinically Documented Visceral Fat Reduction — Tesamorelin carries robust human trial evidence showing up to 15–17.5% reduction in visceral adipose tissue, alongside meaningful lean mass gains — results strong enough to earn FDA approval for HIV-associated lipodystrophy. Ipamorelin further supports lipolysis via IGF-1 upregulation.
Clean Hormonal Profile — Ipamorelin is the most selective GHRP available, stimulating GH release without elevating cortisol, prolactin, or ACTH — unwanted side effects common with older secretagogues like GHRP-6 and GHRP-2. This selectivity makes the blend ideal for research requiring isolated GH axis modulation.
Broad Metabolic & Regenerative Research Applications — The blend is studied across multiple research areas including insulin sensitivity improvement, musculoskeletal tissue repair, bone metabolism, gastrointestinal motility, and cognitive function support — reflecting the wide downstream impact of optimized endogenous GH secretion.